Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

por Gold, Ralf, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Selmaj, Krzysztof, Havrdova, Eva Kubala, Montalban, Xavier, Stefoski, Dusan, Sprenger, Till, Robinson, Randy R., Fam, Sami, Smith, Jonathan, Chalkias, Spyros, Giannattasio, Giorgio, Lima, Gabriel, Castro-Borrero, Wanda
Publicado 2020